The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Lipophilic Efficiency as an Important Metric in Drug Design
Open accessAbstract
Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chemistry lead optimization programs. In this Perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chemistry lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, especially when guided by physiochemical property-based optimization (PPBO). Also highlighted are examples of small structural modifications such as addition of single atoms, small functional groups, and cyclization that produce large increases in LipE. Understanding the factors that may contribute to LipE changes through analysis of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed. Herein we advocate for use of LipE analysis coupled with PPBO and SBDD as an efficient mechanism for drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Fluorine in Pharmaceuticals: Looking Beyond Intuition
Müller, K., Faeh, C., & Diederich, F. (2007) · Science · doi:10.1126/science.1131943 · Cited by 6,596
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
The Many Roles for Fluorine in Medicinal Chemistry
Hagmann, W. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800219f · Cited by 3,578
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Fluorine in Medicinal Chemistry
Böhm, H., Banner, D., Bendels, S., Kansy, M., Kuhn, B., Müller, K., Obst‐Sander, U., & Stahl, M. (2004) · ChemBioChem · doi:10.1002/cbic.200301023 · Cited by 1,572
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
Schönherr, H., & Cernak, T. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303207 · Cited by 1,094
The Methylation Effect in Medicinal Chemistry
Barreiro, E. J., Kümmerle, A. E., & Fraga, C. A. M. (2011) · Chemical Reviews · doi:10.1021/cr200060g · Cited by 1,017
Meyer, H. (1899) · Archiv für Experimentelle Pathologie und Pharmakologie · doi:10.1007/bf01834479 · Cited by 1,014
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Self-citationQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
The maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins
Yang, N. J., & Hinner, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2272-7_3 · Cited by 826
The role of fluorine in medicinal chemistry: Review Article
Shah, P., & Westwell, A. D. (2007) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360701425014 · Cited by 799
Mannhold, R., Poda, G. I., Ostermann, C., & Tetko, I. V. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21494 · Cited by 654
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
Self-citationSolubility and partitioning I: Solubility of nonelectrolytes in water
Yalkowsky, S. H., & Valvani, S. C. (1980) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600690814 · Cited by 577
Methods and Principles in Medicinal Chemistry
(2008) · Methods and principles in medicinal chemistry · doi:10.1002/series6138 · Cited by 514
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Do enthalpy and entropy distinguish first in class from best in class?
Freire, E. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.005 · Cited by 491
Lipophilicity and Its Relationship with Passive Drug Permeation
Liu, X., Testa, B., & Fahr, A. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0303-7 · Cited by 459
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
Ligand configurational entropy and protein binding
Chang, C.-E. A., Chen, W., & Gilson, M. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610494104 · Cited by 436
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization
Pennington, L. D., & Moustakas, D. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01807 · Cited by 408
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Self-citationMolecular determinants of drug–receptor binding kinetics
Pan, A. C., Borhani, D. W., Dror, R. O., & Shaw, D. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.007 · Cited by 373
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Camenisch, G., Alsenz, J., van de Waterbeemd, H., & Folkers, G. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)10019-7 · Cited by 347
Flanagan, M. E., Blumenkopf, T. A., Brissette, W. H., Brown, M. F., Casavant, J. M., Shang-Poa, C., Doty, J. L., Elliott, E. A., Fisher, M. B., Hines, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004286 · Cited by 334
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Howard, E. I., Sanishvili, R., Cachau, R. E., Mitschler, A., Chevrier, B., Barth, P., Lamour, V., Van Zandt, M., Sibley, E., Bon, C., et al. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20015 · Cited by 319
Toward in silico structure-based ADMET prediction in drug discovery
Moroy, G., Martiny, V. Y., Vayer, P., Villoutreix, B. O., & Miteva, M. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.023 · Cited by 302
Ryckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 270
Self-citationCan we estimate the accuracy of ADME–Tox predictions?
Tetko, I. V., Bruneau, P., Mewes, H.-W., Rohrer, D. C., & Poda, G. I. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.013 · Cited by 243
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B., Emmons, T. L., Hall, T., Weinberg, R. A., Gormley, J. A., Williams, J. M., Day, J. E., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.020 · Cited by 227
Meyer, H. (1901) · Archiv für Experimentelle Pathologie und Pharmakologie · doi:10.1007/bf01978064 · Cited by 170
The role of molecular size in ligand efficiency
Reynolds, C. H., Bembenek, S. D., & Tounge, B. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.038 · Cited by 169
Impact of Lipophilic Efficiency on Compound Quality
Tarcsay, Á., Nyíri, K., & Keserű, G. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201388p · Cited by 164
Edwards, M. P., & Price, D. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45023-x · Cited by 147
Self-citationOvercoming Roadblocks in Lead Optimization: A Thermodynamic Perspective
Ruben, A. J., Kiso, Y., & Freire, E. (2005) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00314.x · Cited by 142
Lipophilic Efficiency: The Most Important Efficiency Metric in Medicinal Chemistry
Freeman‐Cook, K. D., Hoffman, R. L., & Johnson, T. W. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.208 · Cited by 139
Self-citationHuang, Q., Johnson, T. W., Bailey, S., Brooun, A., Bunker, K. D., Burke, B. J., Collins, M. R., Cook, A. S., Cui, J. J., Dack, K. N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401805h · Cited by 129
Self-citationBackes, A. C., Zech, B., Felber, B., Klebl, B., & Müller, G. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802580106 · Cited by 110
Idiosyncratic Toxicity: A Convergence of Risk Factors
Ulrich, R. G. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.072905.160823 · Cited by 109
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations
Shultz, M. D. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.030 · Cited by 105
Stepan, A. F., Kauffman, G. W., Keefer, C. E., Verhoest, P. R., & Edwards, M. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008642 · Cited by 102
Self-citationCheng, H., Nair, S. K., Murray, B. W., Almaden, C., Bailey, S., Baxi, S. M., Behenna, D. C., Cho-Schultz, S., Dalvie, D., Dinh, D. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01633 · Cited by 101
Self-citationPlanken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97
Self-citationThe danger hypothesis applied to idiosyncratic drug reactions
Séguin, B., & Uetrecht, J. (2003) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200308000-00001 · Cited by 97
Vanotti, E., Amici, R., Bargiotti, A., Berthelsen, J., Bosotti, R., Ciavolella, A., Cirla, A., Cristiani, C., D’Alessio, R., Forte, B., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700956r · Cited by 93
Chen, X., Tsiang, M., Yu, F., Hung, M., Jones, G. S., Zeynalzadegan, A., Qi, X., JIN, H., Kim, C. U., Swaminathan, S., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.04.054 · Cited by 90
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
A Method for Measuring the Lipophilicity of Compounds in Mixtures of 10
Wenlock, M. C., Potter, T., Barton, P., & Austin, R. P. (2011) · SLAS DISCOVERY · doi:10.1177/1087057110396372 · Cited by 86
Pharmacokinetics and Metabolism in Drug Design
(2012) · Methods and principles in medicinal chemistry · doi:10.1002/9783527645763 · Cited by 86
Kung, P., Rui, E. Y., Bergqvist, S., Bingham, P., Braganza, J., Collins, M. R., Cui, M., Diehl, W. C., Dinh, D. M., Fan, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00515 · Cited by 75
Self-citationKim, D., Kowalchick, J. E., Brockunier, L. L., Parmee, E. R., Eiermann, G. J., Fisher, M. H., He, H., Leiting, B., Lyons, K. A., Scapin, G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070330v · Cited by 68
Ritchie, T. J., Luscombe, C. N., & Macdonald, S. J. F. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800429e · Cited by 62
Schweizer, E., Hoffmann‐Röder, A., Schärer, K., Olsen, J., Fäh, C., Seiler, P., Obst-Sander, U., Wagner, B., Kansy, M., & Diederich, F. (2006) · ChemMedChem · doi:10.1002/cmdc.200600015 · Cited by 62
Second-generation kinase inhibitors
Klebl, B., & Müller, G. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.975 · Cited by 59
Avoiding idiosyncratic DILI: Two is better than one
Kaplowitz, N. (2013) · Hepatology · doi:10.1002/hep.26295 · Cited by 58
Zandt, M. C. V., Sibley, E., McCann, E. E., Combs, K. J., Flam, B. R., Sawicki, D. R., Sabetta, A., Carrington, A. L., Sredy, J., Howard, E., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.07.062 · Cited by 52
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure
Lanier, M. C., Pickens, J., Bigi-Botterill, S. V., Bradshaw‐Pierce, E. L., Chambers, A., Cheruvallath, Z. S., Cole, D. C., Dougan, D. R., Ermolieff, J., Gibson, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00481 · Cited by 46
Halothane-lnduced Hepatic Disease
Touloukian, J., & Kaplowitz, N. (1981) · Seminars in Liver Disease · doi:10.1055/s-2008-1040726 · Cited by 34
Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors
Li, Z., Partridge, J. R., Silva‐Garcia, A., Rademacher, P. M., Betz, A., Xu, Q., Sham, H. L., Hu, Y., Shan, Y., Liu, B., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00384 · Cited by 34
The Added Value of Assessing Ligand–Receptor Binding Kinetics in Drug Discovery
Guo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00273 · Cited by 33
Shamovsky, I. L., de Graaf, C., Alderin, L., Bengtsson, M., Bladh, H., Börjesson, L., Connolly, S., Dyke, H. J., van den Heuvel, M., Johansson, H., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900713y · Cited by 30
Cited by
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
Expanding the medicinal chemistry synthetic toolbox
Boström, J., Brown, D. G., Young, R. J., & Keserü, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.116 · Cited by 665
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Bauer, M. R., Di Fruscia, P., Lucas, S. C. C., Michaelides, I. N., Nelson, J. E., Storer, R. I., & Whitehurst, B. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00370k · Cited by 479
Shultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Metadata
- Authors
- Johnson, T. W., Gallego, R. A., & Edwards, M. P.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-03-28
- Volume
- 61
- Issue
- 15
- Pages
- 6401-6420
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2794867021
- Cited by
- 349
- References
- 73
- FWCI
- 20.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.